Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Y.S. Li, J.J. Zhang, L.Q. Mei & C.X. Tan. (2012) An Improved Procedure for the Preparation of Ribavirin. Organic Preparations and Procedures International 44:4, pages 387-391.
Read now
Read now
Articles from other publishers (20)
Towseef Akram, Irfan Gul, Mahrukh Parveez Zia, Amreena Hassan, Amina Khatun, Riaz Ahmad Shah, Syed Mudasir Ahmad, Nazir Ahmad Ganai, Naveed Anjum Chikan, Won-Il Kim & Nadeem Shabir. (2023) Ribavirin inhibits the replication of infectious bursal disease virus predominantly through depletion of cellular guanosine pool. Frontiers in Veterinary Science 10.
Crossref
Crossref
Lisa Sandmann & Heiner Wedemeyer. (2022) Interferon‐based treatment of chronic hepatitis D. Liver International.
Crossref
Crossref
K.S. Abdelkawy, S.M. El-Haggar, D.H. Ziada, N.F. Ebaid, M.A. El-Magd & F.A. Elbarbry. (2020) The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin. Biomedicine & Pharmacotherapy 121, pages 109657.
Crossref
Crossref
Karina Gonzalez-Aldaco, Arturo Panduro, João R. Rebello Pinho, Erika Martinez-Lopez, Ketti Gleyzer, Nora A. Fierro & Sonia Roman. (2017) High Prevalence of ITPA Alleles Associated with Ribavirin-Induced Hemolytic Anemia Among Mexican Population. Annals of Hepatology 16:2, pages 221-229.
Crossref
Crossref
Dorta Guridi Zaily, Castellanos Fernandez Marlen, Dueñas-Carrera Santiago, Martínez Donato Gillian, Valenzuela Silva Carmen, Cinza Estevez Zurina, Arús Soler Enrique R.Alvarez-Lajonchere Liz, González Fabián Lisset, Lazo del Vallín Sacha & Ferrer Bataille Elena. (2017) Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C. Current Therapeutic Research 85, pages 20-28.
Crossref
Crossref
Nicholas A. Meanwell. (2016) 2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph. Journal of Medicinal Chemistry 59:16, pages 7311-7351.
Crossref
Crossref
Yang Wang, David R McGivern, Liang Cheng, Guangming Li, Stanley M Lemon, Junqi Niu, Lishan Su & Natalia J Reszka-Blanco. (2015) Ribavirin Contributes to Hepatitis C Virus Suppression by Augmenting pDC Activation and Type 1 IFN Production. PLOS ONE 10:8, pages e0135232.
Crossref
Crossref
VICTORIA ZISMANOV, OSHRAT ATTAR-SCHNEIDER, MICHAEL LISHNER, RACHEL HEFFEZ AIZENFELD, SHELLY TARTAKOVER MATALON & LIAT DRUCKER. (2015) Multiple myeloma proteostasis can be targeted via translation initiation factor eIF4E. International Journal of Oncology 46:2, pages 860-870.
Crossref
Crossref
Sarah Allegra, Jessica Cusato, Amedeo De Nicolò, Lucio Boglione, Alberto Gatto, Giuseppe Cariti, Giovanni Di Perri & Antonio D’Avolio. (2015) Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients. Biomedicine & Pharmacotherapy 69, pages 47-55.
Crossref
Crossref
Benjamin M. Wohl, Anton A.A. Smith, Bettina E.B. Jensen & Alexander N. Zelikin. (2014) Macromolecular (pro)drugs with concurrent direct activity against the hepatitis C virus and inflammation. Journal of Controlled Release 196, pages 197-207.
Crossref
Crossref
Warren N. Schmidt, David R. Nelson, Jean–Michel Pawlotsky, Kenneth E. Sherman, David L. Thomas & Raymond T. Chung. (2014) Direct-Acting Antiviral Agents and the Path to Interferon Independence. Clinical Gastroenterology and Hepatology 12:5, pages 728-737.
Crossref
Crossref
Mille B. L. Kryger, Anton A. A. Smith, Benjamin M. Wohl & Alexander N. Zelikin. (2014) Macromolecular Prodrugs for Controlled Delivery of Ribavirin. Macromolecular Bioscience 14:2, pages 173-185.
Crossref
Crossref
Benjamin M. Wohl, Anton A. A. Smith, Mille B. L. Kryger & Alexander N. Zelikin. (2013) Narrow Therapeutic Window of Ribavirin as an Inhibitor of Nitric Oxide Synthesis is Broadened by Macromolecular Prodrugs. Biomacromolecules 14:11, pages 3916-3926.
Crossref
Crossref
Monika Rau, Felix Stickel, Stefan Russmann, Christine N. Manser, Philip P. Becker, Michael Weisskopf, Johannes Schmitt, Michael T. Dill, Jean-François Dufour, Darius Moradpour, David Semela, Beat Müllhaupt & Andreas Geier. (2013) Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection. Journal of Hepatology 58:4, pages 669-675.
Crossref
Crossref
Nicholas A. Meanwell, Stanley V. D'Andrea, Christopher W. Cianci, Ira B. Dicker, Kap-Sun Yeung, Makonen Belema & Mark Krystal. 2013. Drug Discovery. Drug Discovery
439
515
.
Rafael Bárcena, Ana Moreno, Miguel Angel Rodríguez-Gandía, Agustín Albillos, Carlos Arocena, Carlos Blesa, Fernando García-Hoz, Javier Graus, Javier Nuño, Pedro López-Hervás, Luis Gajate, Adolfo Martínez, Teresa Bermejo, María Luisa Mateos & Santos del Campo. (2013) Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period. Journal of Hepatology 58:3, pages 421-426.
Crossref
Crossref
Emmanuel Thomas, Marc G Ghany & T Jake Liang. (2012) The Application and Mechanism of Action of Ribavirin in Therapy of Hepatitis C. Antiviral Chemistry and Chemotherapy 23:1, pages 1-12.
Crossref
Crossref
Sandra Gemma, Stefania Butini, Giuseppe Campiani, Margherita Brindisi, Samantha Zanoli, Maria Pia Romano, Pierangela Tripaldi, Luisa Savini, Isabella Fiorini, Giuseppe Borrelli, Ettore Novellino & Giovanni Maga. (2011) Discovery of potent nucleotide-mimicking competitive inhibitors of hepatitis C virus NS3 helicase. Bioorganic & Medicinal Chemistry Letters 21:9, pages 2776-2779.
Crossref
Crossref
Sheeja M. Krishnan & Narendra M. Dixit. (2011) Ribavirin-Induced Anemia in Hepatitis C Virus Patients Undergoing Combination Therapy. PLoS Computational Biology 7:2, pages e1001072.
Crossref
Crossref
Shigekazu Nagata & Kohki Kawane. 2011.
139
161
.